Niosomes as a targeted drug delivery system in the treatment of breast cancer: preparation, classification and mechanisms of cellular uptake.

IF 4.3 4区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Targeting Pub Date : 2025-07-01 Epub Date: 2025-03-03 DOI:10.1080/1061186X.2025.2468750

Muneeb Ur Rahman, Hafiz Rashid Hussain, Habiba Akram, Muhammad Sarfraz, Muhammad Nouman, Jawad Akbar Khan, Memona Ishtiaq

{"title":"Niosomes as a targeted drug delivery system in the treatment of breast cancer: preparation, classification and mechanisms of cellular uptake.","authors":"Muneeb Ur Rahman, Hafiz Rashid Hussain, Habiba Akram, Muhammad Sarfraz, Muhammad Nouman, Jawad Akbar Khan, Memona Ishtiaq","doi":"10.1080/1061186X.2025.2468750","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer (BC) remains one of the significant health issues across the globe, being diagnosed in millions of women worldwide annually. Conventional therapeutic options have substantial adverse effects due to their non-specificity and limited drug bioavailability. Niosomes, being novel drug delivery systems formed from non-ionic surfactants, with or without cholesterol and charge-inducing agents, are used as therapeutic options in treating BC. Their formulation by various methods enhances the therapeutic efficacy and bioavailability and minimises side effects. Niosomal formulation of tamoxifen exhibits target drug delivery with enhanced stability, whereas docetaxel and methotrexate show sustained and controlled drug release, respectively. 5-Fluorouracil, doxorubicin, paclitaxel, cyclophosphamide and epirubicin show improved cytotoxic effects against BC when combined with other agents. Furthermore, repurposed niosomal formulations of anti-cancer drugs show improved penetration, reduced tumour volume and significantly enhanced anti-tumour effect. This review article focuses on the composition of niosomes and their application in BC treatment and then examines how niosomes could contribute to BC research.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"916-932"},"PeriodicalIF":4.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2025.2468750","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer (BC) remains one of the significant health issues across the globe, being diagnosed in millions of women worldwide annually. Conventional therapeutic options have substantial adverse effects due to their non-specificity and limited drug bioavailability. Niosomes, being novel drug delivery systems formed from non-ionic surfactants, with or without cholesterol and charge-inducing agents, are used as therapeutic options in treating BC. Their formulation by various methods enhances the therapeutic efficacy and bioavailability and minimises side effects. Niosomal formulation of tamoxifen exhibits target drug delivery with enhanced stability, whereas docetaxel and methotrexate show sustained and controlled drug release, respectively. 5-Fluorouracil, doxorubicin, paclitaxel, cyclophosphamide and epirubicin show improved cytotoxic effects against BC when combined with other agents. Furthermore, repurposed niosomal formulations of anti-cancer drugs show improved penetration, reduced tumour volume and significantly enhanced anti-tumour effect. This review article focuses on the composition of niosomes and their application in BC treatment and then examines how niosomes could contribute to BC research.

查看原文本刊更多论文

乳小体作为治疗乳腺癌的靶向药物传递系统：制备、分类和细胞摄取机制。

乳腺癌仍然是全球重大的健康问题之一，每年全世界有数百万妇女被诊断出患有乳腺癌。传统的治疗方案由于其非特异性和有限的药物生物利用度而具有实质性的不良反应。Niosomes是一种由非离子表面活性剂形成的新型药物传递系统，有或没有胆固醇和电荷诱导剂，被用作治疗BC的治疗选择。他们的配方通过各种方法提高治疗效果和生物利用度，并尽量减少副作用。他莫昔芬的Niosomal剂型表现出靶向药物递送和增强的稳定性，而多西他赛和甲氨蝶呤分别表现出持续和可控的药物释放。5-氟尿嘧啶、阿霉素、紫杉醇、环磷酰胺和表柔比星与其他药物联合使用时，对BC的细胞毒性作用得到改善。此外，抗癌药物的重定向niosomal制剂显示出更好的穿透性，减少肿瘤体积，并显着增强抗肿瘤效果。本文综述了乳质体的组成及其在BC治疗中的应用，并探讨了乳质体对BC研究的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Targeting 医学-药学

CiteScore

9.10

自引率

0.00%

发文量

165

审稿时长

2 months

期刊介绍： Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.